Table 2.
Use of pelvic lymph node dissection (PLND) by tumor risk factors and surgical approach, cases diagnosed 2004–2005
| All Patients (n=4,374) | MIRP (n=1,085) | ORP (n=3,289) | ||||
|---|---|---|---|---|---|---|
| Characteristic | N | % PLND | N | % PLND | N | % PLND |
| Clinical stage | ||||||
| T1 | 1,561 | 68% | 273 | 42% | 1,288 | 78% |
| T2 | 1.464 | 73% | 175 | 53% | 1,289 | 82% |
| T3 | 65 | 74% | 10 | 56% | 55 | 80% |
| Numeric PSA* | ||||||
| ≤10 ng/ml | 2072 | 69% | 317 | 40% | 1,775 | 80% |
| >10 ng/ml | 593 | 81% | 91 | 60% | 502 | 86% |
| Gleason Score | ||||||
| 2–6 | 1,200 | 63% | 150 | 30% | 1,050 | 75% |
| 7+ | 1,890 | 76% | 308 | 52% | 1,582 | 84% |
MIRP: minimally invasive radical prostatectomy, ORP: open radical prostatectomy
Men missing numeric PSA information (n=647 of those diagnosed 2004–2005) excluded from analysis.